Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock (Tables)

Common Stock (Tables)

3 Months Ended

Mar. 31, 2013


	Number of Optioned Common Shares			Weighted Average Exercise Price
	#			$
Balance, December 31, 2012		804,781			11.34
Option grants		182,182			11.97
Option expirations		(3,061	)		4.11
Option exercises		(3,475	)		3.00
Option forfeitures		(200	)		14.49

Balance, March 31, 2013		980,227			11.51

Summary of fair value option award


	Three months ended March 31,
	2013			2012

Risk-free interest rates		1.12	%		—

Expected dividend yield		0	%		—

Expected life		5.9 years			—

Expected volatility		88	%		—

Summary of share-based compensation expense for stock options and restricted stock


	Three Months Ended
	March 31,
	2013		2012
	$		$
Research and development		312		135
General and administrative		436		185


Total share-based compensation		748		320

Summary of restricted stock unit award activity


	2013					2012
	Stock Awards #			Weighted- Average Grant Date Fair Value $		Stock Awards #		Weighted- Average Grant Date Fair Value $
Outstanding January 1		172,035			13.01		—		—
Granted		225,345			11.96		—		—
Vested		(13,899	)		13.00		—		—
Forfeited or expired		(562	)		13.00		—		—

Outstanding March 31		382,919			12.39		—		—

Summary of fair value of warrants issued


	Three Months Ended March 31,
	2013			2012

Risk-free interest rates		0.31	%		0.66	%

Expected dividend yield		0	%		0	%

Expected life		2.6 years			3.6 years

Expected volatility		44	%		77	%

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details